FiercePharma says: Roche disappointed analysts this quarter, and its seven percent has been blamed on lower demand for Tamiflu. Sales fell from 12.4 billion Swiss francs to 11.5 billion francs, well below analysts' 11.8 billion francs mark. Revenue slid nine percent to 9 billion francs. The company maintains that they have seen no change in Avastin's sales since Europe decided to review the drug's breast cancer use.

Highlights

• Sales of cancer medicines continue to grow strongly, rising 8%.
• Operational Excellence initiative's Group-wide review of structures and processes well under way, with measures to be announced before year-end. Aim is to accelerate productivity improvements and strengthen innovation capacity.
• Roche named Supersector Leader in Healthcare in the Dow Jones Sustainability Indexes (DJSI) for second year running.
• Roche confirms full-year outlook.

Roche's website: http://www.roche.com/
Full release: Roche release

Related Articles:
GSK sues Roche for patent infringement
Amid Western cuts, Roche staffs up in China
CEO: Roche eyes cuts in primary-care sales
Court overturns $10.5M Accutane verdict
Avastin snubbed yet again by U.K. cost agency
Roche fashions cost-saving overhaul